Phase IIb Study of STA-2 in Patients With Chronic Stable Angina
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01239511 |
Recruitment Status :
Completed
First Posted : November 11, 2010
Results First Posted : August 27, 2014
Last Update Posted : August 27, 2014
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Chronic Stable Angina | Drug: green tea polyphenols (STA-2) | Phase 2 |
The objective of this study is to evaluate the dose-response of three different dose levels of STA-2 (900 mg daily, 1800 mg daily and 2700 mg daily for 42 days) versus placebo in patients with chronic stable angina.
Treatment Group A:
150 mg STA-2, 2 capsules t.i.d., after meal (900 mg STA-2 total dose per day)
Treatment Group B:
300 mg STA-2, 2 capsules t.i.d., after meal (1800 mg STA-2 total dose per day)
Treatment Group C:
450 mg STA-2, 2 capsules t.i.d., after meal (2700 mg STA-2 total dose per day)
Placebo Group:
Placebo capsule, 2 capsules t.i.d., after meal
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 186 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Investigator) |
Primary Purpose: | Treatment |
Official Title: | A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Dose-Response and Safety of STA-2 in Patients With Chronic Stable Angina |
Study Start Date : | November 2010 |
Actual Primary Completion Date : | April 2012 |
Actual Study Completion Date : | April 2012 |
Arm | Intervention/treatment |
---|---|
Placebo Comparator: Placebo group
placebo capsule 2# t.i.d./day
|
Drug: green tea polyphenols (STA-2)
2 capsules t.i.d., after meal |
Experimental: Treatment Group A
150 mg STA-2, 2 capsules t.i.d., after meal (900 mg STA-2 total dose per day)
|
Drug: green tea polyphenols (STA-2)
2 capsules t.i.d., after meal |
Experimental: Treatment Group B
300 mg STA-2, 2 capsules t.i.d., after meal (1800 mg STA-2 total dose per day)
|
Drug: green tea polyphenols (STA-2)
2 capsules t.i.d., after meal |
Experimental: Treatment Group C
450 mg STA-2, 2 capsules t.i.d., after meal (2700 mg STA-2 total dose per day)
|
Drug: green tea polyphenols (STA-2)
2 capsules t.i.d., after meal |
- Change in Total Exercise Time (Seconds) [ Time Frame: 6 weeks after the first exercise tolerance testing is conducted ]the time difference of total exercise time from V2 to V5 compare to placebo
- Change in Time to Onset of Angina From Baseline to the Final Visit [ Time Frame: 6 weeks ]
- Changes in Time to 1mm ST-segment Depression During ETT From Baseline to Final Visit [ Time Frame: 6 weeks ]
- Changes in Time to Maximum ST-segment Depression During ETT From Baseline to the Final Visit [ Time Frame: 6 weeks ]
- Changes in Angina Frequency in Subject's Diary From Baseline to All Visits [ Time Frame: 6 weeks ]
- Change in Consumption of Short-acting Nitrates From Baseline to All Visits [ Time Frame: 6 weeks ]
- Change in Pharmacological Parameters (Oxidized-LDL), Isoprostane and High-sensitivity Hs-CRP From Baseline to All Visits [ Time Frame: 6 weeks ]
- Change in Lipid Profiles (HDL-C, LDL-C, Total Cholesterol, Triglyceride) From Baseline to All Visits [ Time Frame: 6 weeks ]
- Dose-response Relationship of Three Different Dose Levels of STA-2 Versus Placebo Control in Change in Total Exercise Time. [ Time Frame: 6 weeks ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 20 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Male or female aged ≧ 20 years;
- Subjects weight > 50 kg
- subjects who had more than 50% coronary stenosis documented by catheterization or ever received coronary intervention;
- The two ETT results at screening (Visit 1) and baseline (Visit 2) show greater than or equal to 1 mm ST-segment depression within exercise duration;
- The difference in exercise duration between screening (Visit 1) and baseline (Visit 2) do not exceed 20% of the longer test;
- Able to provide written informed consent.
Exclusion Criteria:
- Subjects with pacemaker rhythm, unstable angina or myocardial infarction within the preceding 3 months;
- Subjects with heart failure (New York Heart Association class III or IV), uncorrected valvular or congenital heart disease, subjects who need digoxin or digitalis;
- Subjects with any resting EKG abnormalities preventing the interpretation of ischemia as judged by the investigator;
- Subjects with COPD requiring bronchodilators;
- Subjects with impaired hepatic function (defined as AST or ALT > 2X the upper limit of normal values), or impaired renal function (defined as serum creatinine > 1.5 mg/dL), or diagnosis of any chronic renal/hepatic disease;
- Subjects with documented evidence of gastroduodenal ulcer disease, gastrointestinal bleeding or other gastrointestinal disease within the preceding 3 months as judged by investigator;
- Subjects who have a history or evidence of a medical condition that would expose them to an undue risk of a significant adverse event or interfere with safety assessments during the course of the trial, including but not limited to hepatic, renal, respiratory, cardiovascular, endocrine, immune, neurological, or hematological disease as determined by the clinical judgment of the investigator;
- Subject with any conditions that could interfere the performance of exercise tolerance test as judged by investigator (e.g., knee/ankle arthropathy, Parkinsonism, stoke);
-
Female subjects of childbearing potential who:
- are lactating;
- have positive pregnancy test (urine) at V1;
- Subject has received any investigational agent within 28 days prior to the first dose of investigational product;
- Subjects who have had administered STA-2 in prior clinical trial.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01239511
Taiwan | |
Kaohsiung Medical University Chung-Ho Memorial Hospital | |
Kaohsiung, Taiwan | |
Chi Mei Medical Center | |
Tainan, Taiwan | |
National Taiwan University Hospital | |
Taipei, Taiwan | |
Taipei Medical University-Shuang Ho Hospital | |
Taipei, Taiwan | |
Taipei Veterans General Hospital | |
Taipei, Taiwan |
Principal Investigator: | Chuen-Den Tseng, MD, Ph.D | Department of Cardiology National Taiwan University Hospital |
Responsible Party: | Sinphar Pharmaceutical Co., Ltd |
ClinicalTrials.gov Identifier: | NCT01239511 |
Other Study ID Numbers: |
MCCD09004A |
First Posted: | November 11, 2010 Key Record Dates |
Results First Posted: | August 27, 2014 |
Last Update Posted: | August 27, 2014 |
Last Verified: | August 2014 |
Angina Pectoris Angina, Stable Myocardial Ischemia Heart Diseases Cardiovascular Diseases |
Vascular Diseases Chest Pain Pain Neurologic Manifestations |